FDA expands label for long-acting parasiticide for dogsApril 3, 2026The U.S. Food and Drug Administration (FDA) has approved an expanded label for a long-acting injectable parasiticide for dogs, adding protection against two emerging tick species for up to 12 months.
SPONSORED CONTENTHill's Prescription Diet Metabolic Weight + j/dNutrition to help mobility in as little as 1 month. 88% of pets lost weight in 2 months at home with Metabolic nutrition. + Learn More
FDA approves first generic injectable robenacoxib for dogs and catsMarch 23, 2026The robenacoxib injectable is for the control of postoperative pain and inflammation associated with soft tissue surgery in canine patients; orthopedic surgery, spaying, or neutering in feline patients.
FDA approves generic NSAID for post-op pain and inflammation in catsFebruary 10, 2026 The product is indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats at least four months old and weighing at least 5.5 lbs.
FDA accepts safety data for canine longevity drugJanuary 13, 2026Loyal advances toward market approval with acceptance of Target Animal Safety section for its senior dog lifespan extension drug, LOY-002.
FDA approves generic tablet for feline hyperthyroidismAugust 5, 2025The U.S. Food and Drug Administration (FDA) has approved Methimazole Coated Tablets for the treatment of feline hyperthyroidism. The product has been evaluated for safety, effectiveness, and bioequivalence to the approved reference drug.
Cefovecin sodium injection for skin infections OK-ed by FDAJuly 8, 2025The U.S. Food and Drug Administration (FDA) has approved the first generic cefovecin sodium injection to treat skin infections, including abscesses and wounds caused by specific bacterial strains, in dogs and cats.
FDA unveils framework to curb animal testing in drug developmentApril 11, 2025The U.S. Food and Drug Administration (FDA) aims to replace animal testing with ‘more effective, human-relevant methods’ in developing monoclonal antibody therapies and other drugs.
FDA conditionally approves feline ventricular hypertrophy medMarch 20, 2025The sirolimus delayed-release tablet is prescribed to help manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).
Broad canine oral parasiticide gets FDA approvalOctober 8, 2024The single monthly dose parasiticide is recommended to protect against six parasites, including fleas, ticks, heartworms, hookworms, and tapeworms.
Canine dermatology drug gets FDA approvalSeptember 19, 2024The once-daily oral JAK inhibitor for control of pruritus associated with allergic dermatitis and control of atopic dermatitis can be prescribed to dogs at least 12 months of age
